Journals A-Z
All Subjects
Free Journals
sciepub.com
Journal of Cancer Research and Treatment
ISSN (Print): 2374-1996 ISSN (Online): 2374-2003 Website: https://www.sciepub.com/journal/jcrt Editor-in-chief: Jean Rommelaere
Open Access
Journal Browser
Go
Issue 1, Volume 12
Article Metrics
  • 3575
    Views
  • 4865
    Saves
  • 0
    Citations
  • 3
    Likes
Export Article
Journal of Cancer Research and Treatment. 2024, 12(1), 1-7
DOI: 10.12691/jcrt-12-1-1
Open AccessReview Article

Tumor Markers of Colorectal Carcinoma: New Perspectives

Ahmed M. Kabel1, and Shaimaa M. Kabel2

1Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta 31527, Egypt

2Zoology Department, Faculty of Science, Tanta University, Tanta 31527, Egypt

Pub. Date: March 01, 2024
View Full Text Full Text PDF (384 KB) Full Text ePUB(106 KB)

Cite this paper:
Ahmed M. Kabel and Shaimaa M. Kabel. Tumor Markers of Colorectal Carcinoma: New Perspectives. Journal of Cancer Research and Treatment. 2024; 12(1):1-7. doi: 10.12691/jcrt-12-1-1

Abstract

Colorectal carcinoma (CRC) represents one of the most commonly diagnosed malignant tumors worldwide. In spite of the continuous progress in diagnostic and therapeutic tools, CRC significantly contributes to cancer-related deaths all over the world. Early detection and treatment of patients with CRC may have a positive impact on prognosis, as the delay of diagnosis carries the risk of poor prognosis. Recently, new tumor biomarkers were discovered which can alone or together with the existing tests recognize either the predisposing factors or the early stages of CRC. Also, these biomarkers have the potential to determine the appropriate treatment algorithms by selecting the proper chemotherapeutic agents that can induce remission in a broad spectrum of patients. This review throws light on the tumor markers of CRC and their role in early diagnosis and determination of prognosis and the suitable lines of management of patients with CRC.

Keywords:
colorectal cancer tumor markers diagnosis management

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Shao B, Zhu M, Shen K, Luo L, Du P, Li J, Xu J, Deng Y, Lin N, Wu J, Hu W. Disease Burden of Total and Early-Onset Colorectal Cancer in China from 1990 to 2019 and Predictions of Cancer Incidence and Mortality. Clin Epidemiol. 2023; 15: 151-163.
 
[2]  Topdagi O, Timuroglu A. Eighteen Years’ Retrospective Review of Colorectal Cancer Cases in Eastern Population. Eurasian J Med 2018; 50(1): 19-22.
 
[3]  Dutta A, Pratiti R, Kalantary A, Aboulian A, Shekherdimian S. Colorectal Cancer: A Systematic Review of the Current Situation and Screening in North and Central Asian Countries. Cureus. 2023; 15(1): e33424.
 
[4]  Bodaghi A, Fattahi N, Ramazani A. Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases. Heliyon. 2023; 9(2): e13323.
 
[5]  Thannickal HH, Eltoum N, Henderson NL, Wallner LP, Wagner LI, Wolff AC, Rocque GB. Physicians' Hierarchy of Tumor Biomarkers for Optimizing Chemotherapy in Breast Cancer Care. Oncologist. 2024; 29(1): e38-e46.
 
[6]  Lech G, Słotwiński R, Słodkowski M, Krasnodębski IW. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J Gastroenterol 2016; 22(5): 1745-55.
 
[7]  Zhu Q, Liu M, Dai L, Ye H, Han S, Zhang J-Y. Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis. Autoimmun rev 2013; 12(12): 1123-8.
 
[8]  Sarhadi VK, Armengol G. Molecular Biomarkers in Cancer. Biomolecules 2022; 12(8): 1021.
 
[9]  Kabel AM, Abd Elmaaboud MA. Cancer: Role of Nutrition, Pathogenesis, Diagnosis and Management. World Journal of Nutrition and Health 2014; 2(4): 48-51.
 
[10]  Vukobrat-Bijedic Z, Husic-Selimovic A, Sofic A, Bijedic N, Bjelogrlic I, Gogov B, et al. Cancer Antigens (CEA and CA 19-9) as Markers of Advanced Stage of Colorectal Carcinoma. Med Arch 2013; 67(6):397-401.
 
[11]  Danese E, Montagnana M. Epigenetics of colorectal cancer: emerging circulating diagnostic and prognostic biomarkers. Ann Transl Med 2017; 5(13): 279.
 
[12]  Ajithkumar P, Vasantharajan SS, Pattison S, McCall JL, Rodger EJ, Chatterjee A. Exploring Potential Epigenetic Biomarkers for Colorectal Cancer Metastasis. Int J Mol Sci. 2024; 25(2): 874.
 
[13]  Li X, Li J, Li J, Liu N, Zhuang L. Development and validation of epigenetic modification-related signals for the diagnosis and prognosis of colorectal cancer. BMC Genomics. 2024; 25(1): 51.
 
[14]  Stürzlinger H, Conrads-Frank A, Eisenmann A, et al. Stool DNA testing for early detection of colorectal cancer: systematic review using the HTA Core Model® for Rapid Relative Effectiveness Assessment. Ger Med Sci 2023; 21: Doc06.
 
[15]  Bustin SA, Murphy J. RNA biomarkers in colorectal cancer. Methods 2013; 59(1): 116-25.
 
[16]  Pekarek L, Torres-Carranza D, Fraile-Martinez O, García-Montero C, Pekarek T, Saez MA, Rueda-Correa F, Pimentel-Martinez C, Guijarro LG, Diaz-Pedrero R, Alvarez-Mon M, Ortega MA. An Overview of the Role of MicroRNAs on Carcinogenesis: A Focus on Cell Cycle, Angiogenesis and Metastasis. Int J Mol Sci. 2023; 24(8): 7268.
 
[17]  Fadaka AO, Pretorius A, Klein A. Biomarkers for Stratification in Colorectal Cancer: MicroRNAs. Cancer Control 2019; 26(1): 1073274819862784.
 
[18]  Chen B, Xia Z, Deng YN, Yanfang Yang Y, Zhang P, Zhu H, et al. Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis. Open Biol 2019; 9(1): 180212.
 
[19]  Toma SC, Ungureanu BS, Patrascu S, Surlin V, Georgescu I. Colorectal Cancer Biomarkers- A New Trend in Early Diagnosis. Curr Health Sci J 2018; 44(2): 140-6.
 
[20]  Liu HN, Yao C, Wang XF, et al. Diagnostic and economic value of carcinoembryonic antigen, carbohydrate antigen 19-9, and carbohydrate antigen 72-4 in gastrointestinal cancers. World J Gastroenterol. 2023; 29(4) :706-30.
 
[21]  Hall C, Clarke L, Pal A, Buchwald P, Eglinton T, Wakeman C, et al. A Review of the Role of Carcinoembryonic Antigen in Clinical Practice. Ann Coloproctol 2019; 35(6): 294-305.
 
[22]  Liao L, Tang J, Hong Z, Jiang W, Li Y, Kong L, Han K, Hou Z, Zhang C, Zhou C, Zhang L, Sui Q, Xiao B, Mei W, Yu J, Yang W, Pan Z, Ding PR. The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study. BMC Cancer. 2024; 24(1): 164.
 
[23]  Wach MM, Nunns G, Hamed A, Derby J, Jelinek M, Tatsuoka C, Holtzman MP, Zureikat AH, Bartlett DL, Ahrendt SA, Pingpank JF, Choudry MHA, Ongchin M. Normal CEA Levels After Neoadjuvant Chemotherapy and Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion Predict Improved Survival from Colorectal Peritoneal Metastases. Ann Surg Oncol. 2024 Jan 25.
 
[24]  Tong G, Xu W, Zhang G, Liu J, Zheng Z, Chen Y, et al. The role of tissue and serum carcinoembryonic antigen in stages I to III of colorectal cancer-A retrospective cohort study. Cancer Med 2018; 7(11): 5327-38.
 
[25]  Holm M, Saraswat M, Joenväärä S, Ristimäki A, Haglund C, Renkonen R. Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics. PLoS One 2018; 13(4): e0195354.
 
[26]  Bardet S, Ciappuccini R, Lamartina L, Leboulleux S. Unusual increase in carcinoembryonic antigen despite response to selpercatinib in two patients with medullary thyroid cancer. Eur Thyroid J. 2022; 11(2): e210104.
 
[27]  Saito G, Sadahiro S, Kamata H, Miyakita H, Okada K, Tanaka A, et al. Monitoring of Serum Carcinoembryonic Antigen Levels after Curative Resection of Colon Cancer: Cutoff Values Determined according to Preoperative Levels Enhance the Diagnostic Accuracy for Recurrence. Oncology 2017; 92(5): 276-82.
 
[28]  Ning S, Wei W, Li J, Hou B, Zhong J, Xie Y, Liu H, Mo X, Chen J, Zhang L. Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients. J Cancer. 2018; 9(3): 494-501.
 
[29]  Shin JK, Kim HC, Lee WY, Yun SH, Cho YB, Huh JW, et al. High preoperative serum CA 19-9 levels can predict poor oncologic outcomes in colorectal cancer patients on propensity score analysis. Ann Surg Treat Res 2019; 96(3): 107-15.
 
[30]  Vacante M, Borzì AM, Basile F, Biondi A. Biomarkers in colorectal cancer: Current clinical utility and future perspectives. World J Clin Cases 2018; 6(15): 869-81.
 
[31]  Duan L, Yang W, Wang X, Zhou W, Zhang Y, Liu J, et al. Advances in prognostic markers for colorectal cancer. Expert Rev Mol Diagn 2019; 19(4): 313-24.
 
[32]  Zeinalian M, Hashemzadeh-Chaleshtori M, Salehi R, Emami MH. Clinical Aspects of Microsatellite Instability Testing in Colorectal Cancer. Adv Biomed Res 2018; 7: 28.
 
[33]  Kang S, Na Y, Joung SY, Lee SI, Oh SC, Min BW. The significance of microsatellite instability in colorectal cancer after controlling for clinicopathological factors. Medicine (Baltimore) 2018; 97(9): e0019.
 
[34]  Jo WS, Carethers JM. Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark 2006; 2(1-2): 51-60.
 
[35]  Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer Res. 2012; 5(1): 19-27.
 
[36]  Wang W, Li YF, Sun XW, Chen G, Zhan YQ, Huang CY, et al. Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-II colon cancer patients. Chin J Cancer 2010; 29(8): 761-7.
 
[37]  Nguyen HT, Duong HQ. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy. Oncol Lett 2018; 16(1): 9-18.
 
[38]  Wang D, Nakayama M, Hong CP, Oshima H, Oshima M. Gain-of-Function p53 Mutation Acts as a Genetic Switch for TGFβ Signaling-Induced Epithelial-to-Mesenchymal Transition in Intestinal Tumors. Cancer Res. 2024; 84(1): 56-68.
 
[39]  Chen LC, Yang PC, Chen CY, Chiang SF, Chen TW, Chen WT, Ke TW, Liang JA, Shiau AC, Chao KSC, Huang KC. Dual Inhibition of B7-H3 and EGFR Overcomes Acquired Chemoresistance in Colon Adenocarcinoma. J Cancer. 2024; 15(6): 1750-1761.
 
[40]  Nakayama M, Oshima M. Mutant p53 in colon cancer. J Mol Cell Biol 2019; 11(4): 267-76.
 
[41]  Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, et al. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol 2016; 22(28): 6345-61.
 
[42]  Patel JN, Fong MK, Jagosky M. Colorectal Cancer Biomarkers in the Era of Personalized Medicine. J Pers Med 2019; 9(1): 3.
 
[43]  Bond CE, Whitehall VLJ. How the BRAF V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications. Gastroenterol Res Pract 2018; 2018: 9250757.
 
[44]  Afrăsânie VA, Marinca MV, Alexa-Stratulat T, Gafton B, Păduraru M, Adavidoaiei AM, et al. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician. Radiol Oncol 2019; 53(3): 265-74.
 
[45]  Wang Q, Shi YL, Zhou K, Wang LL, Yan ZX, Liu YL, et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis 2018; 9(7): 739.
 
[46]  Mei ZB, Duan CY, Li CB, Cui L, Ogino S. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2016; 27(10): 1836-48.
 
[47]  Hall DCN, Benndorf RA. Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited. Cell Mol Life Sci. 2022;79(7): 393.
 
[48]  Hamada T, Nowak JA, Ogino S. PIK3CA mutation and colorectal cancer precision medicine. Oncotarget 2017; 8(14): 22305-6.
 
[49]  Rodrigues D, Longatto-Filho A, Martins SF. Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options. Biomed Res Int 2016; 2016: 6896024.
 
[50]  Cortejoso L, García MI, García-Alfonso P, González-Haba E, Escolar F, Sanjurjo M, et al. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol 2013; 71(6): 1463-72.
 
[51]  Balasubramanian S, Priyathersini N, Johnson T. Expression of Vascular Endothelial Growth Factor (VEGF) in Colorectal Adenoma and Carcinoma in a Tertiary Care Center. Cureus. 2022; 14(11): e31393.
 
[52]  Jang HJ, Kim BJ, Kim JH, Kim HS. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Oncotarget 2017; 8(42): 73009-16.
 
[53]  Kobori T, Tanaka C, Tameishi M, Urashima Y, Ito T, Obata T. Role of Ezrin/Radixin/Moesin in the Surface Localization of Programmed Cell Death Ligand-1 in Human Colon Adenocarcinoma LS180 Cells. Pharmaceuticals (Basel). 2021; 14(9): 864.
 
[54]  Fathi A, Mosaad H, Hussein S, Roshdy M, Ismail EI. Prognostic significance of CD133 and ezrin expression in colorectal carcinoma. IUBMB Life 2017; 69(5): 328-40.
 
[55]  Leiphrakpam PD, Rajput A, Mathiesen M, Agarwal E, Lazenby AJ, Are C, et al. Ezrin expression and cell survival regulation in colorectal cancer. Cell Signal 2014; 26(5): 868-79.
 
[56]  Bărbălan A, Nicolaescu AC, Măgăran AV, Mercuţ R, Bălăşoiu M, Băncescu G, et al. Immunohistochemistry predictive markers for primary colorectal cancer tumors: where are we and where are we going?. Rom J Morphol Embryol 2018; 59(1): 29-42.
 
[57]  Theiss AP, Chafin D, Bauer DR, Grogan TM, Baird GS. Immunohistochemistry of colorectal cancer biomarker phosphorylation requires controlled tissue fixation. PLoS One 2014; 9(11): e113608.
 
[58]  Pastuszak M, Groszewski K, Pastuszak M, Dyrla P, Wojtuń S, Gil J. Cytokeratins in gastroenterology. Systematic review. Prz Gastroenterol 2015; 10(2): 61-70.
 
[59]  Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, Wilcox-Fogel N, Forgó E, Rajendran PS, Miranda SP, Hisamori S, Hutchison J, Kalisky T, Qian D, Wolmark N, Fisher GA, van de Rijn M, Clarke MF. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med. 2016; 374(3): 211-22.
 
[60]  Haraldsson S, Klarskov L, Nilbert M, Bernstein I, Bonde J, Holck S. Differential expression of CK20, β-catenin, and MUC2/5AC/6 in Lynch syndrome and familial colorectal cancer type X. BMC Clin Pathol 2017; 17: 11.
 
[61]  Tomasello G, Barni S, Turati L, Ghidini M, Pezzica E, Passalacqua R, et al. Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis. Clin Colorectal Cancer 2018; 17(2): 97‐103.
 
[62]  Dum D, Lennartz M, Menz A, Kluth M, Hube-Magg C, Weidemann S, Fraune C, Luebke AM, Hornsteiner L, Bernreuther C, Simon R, Clauditz TS, Sauter G, Uhlig R, Hinsch A, Kind S, Jacobsen F, Möller K, Wilczak W, Steurer S, Minner S, Burandt E, Marx AH, Krech T, Lebok P. Villin expression in human tumors: a tissue microarray study on 14,398 tumors. Expert Rev Mol Diagn. 2022; 22(6): 665-675.
 
[63]  Graule J, Uth K, Fischer E, Centeno I, Galván JA, Eichmann M, et al. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. Clin Epigenetics 2018;10(1):120.
 
[64]  Li Z, Rock JB, Roth R, Lehman A, Marsh WL, Suarez A, et al. Dual Stain With SATB2 and CK20/Villin Is Useful to Distinguish Colorectal Carcinomas From Other Tumors. Am J Clin Pathol 2018; 149(3): 241-6.
 
[65]  Gatalica Z, Stafford P, Vranic S. Alpha-methylacyl-CoA racemase (AMACR) protein is upregulated in early proliferative lesions of the breast irrespective of apocrine differentiation. Hum Pathol. 2022; 129: 40-46.
 
[66]  Kabel, A. M., Ashour, A. M., Ali, D. A., & Arab, H. H. (2021). The immunomodulatory effects of topiramate on azoxymethane-induced colon carcinogenesis in rats: The role of the inflammatory cascade, vascular endothelial growth factor, AKT/mTOR/MAP kinase signaling and the apoptotic markers. International immunopharmacology, 98, 107830.
 
[67]  Kaushal A, Kaur N, Sharma S, Sharma AK, Kala D, Prakash H, Gupta S. Current Update on Biomarkers for Detection of Cancer: Comprehensive Analysis. Vaccines (Basel). 2022 Dec 13; 10(12): 2138.
 
[68]  Shukla N, Adhya AK, Rath J. Expression of Alpha - Methylacyl - Coenzyme A Racemase (AMACR) in Colorectal Neoplasia. J Clin Diagn Res 2017; 11(4): EC35‐EC38.
 
[69]  Ku SC, Liu HL, Su CY, Yeh IJ, Yen MC, Anuraga G, Ta HDK, Chiao CC, Xuan DTM, Prayugo FB, Wang WJ, Wang CY. Comprehensive analysis of prognostic significance of cadherin (CDH) gene family in breast cancer. Aging (Albany NY). 2022; 14(20): 8498-8567.
 
[70]  Abouelkhair, M. B., Mabrouk, S. H., Zaki, S. S. A., Nada, O. H., & Hakim, S. A. (2021). The Diagnostic Value of Cadherin 17 and CDX2 Expression as Immunohistochemical Markers in Colorectal Adenocarcinoma. Journal of gastrointestinal cancer, 52(3), 960–9.
 
[71]  Zhang YJ, Chen JW, He XS, Zhang HZ, Ling YH, Wen JH, et al. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas. EBioMedicine 2018; 28: 62-9.
 
[72]  Ma C, Olevian D, Miller C, Herbst C, Jayachandran P, Kozak MM, et al. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer. Mod Pathol 2019; 32(8): 1217-31.
 
[73]  Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, Hollebecque A, Dartigues P, et al. Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol 2019; 11: 1758835919856494.
 
[74]  Druzhkova I, Ignatova N, Prodanets N, Kiselev N, Zhukov I, Shirmanova M, et al. E-Cadherin in Colorectal Cancer: Relation to Chemosensitivity. Clin Colorectal Cancer 2019; 18(1): e74‐e86.
 
[75]  Gnosa SP, Puig Blasco L, Piotrowski KB, Freiberg ML, Savickas S, Madsen DH, Auf dem Keller U, Kronqvist P, Kveiborg M. ADAM17-mediated EGFR ligand shedding directs macrophage-promoted cancer cell invasion. JCI Insight. 2022; 7(18): e155296.
 
[76]  García-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, et al. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. Front Oncol 2019; 9: 849.
 
[77]  Akbari M, Shomali N, Faraji A, Shanehbandi D, Asadi M, Mokhtarzadeh A, et al. CD133: An emerging prognostic factor and therapeutic target in colorectal cancer. Cell Biol Int 2020; 44(2): 368-80.
 
[78]  Abdou Hassan W, Muqresh MA, Omer M. The Potential Role of CD44 and CD133 in Colorectal Stem Cell Cancer. Cureus. 2022; 14(10): e30509.
 
[79]  Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer. 2011; 2(4): 466-74.
 
[80]  Kabel AM. Tumor protein p53: Novel aspects of an old tumor marker. J Cancer Res Treat 2015; 3(2): 25-7.
 
[81]  Zawacka-Pankau JE. The Role of p53 Family in Cancer. Cancers (Basel). 2022; 14(3): 823.
 
[82]  Bojuwoye MO, Olokoba AB, Ogunlaja OA, Agodirin SO, Ibrahim OK, Okonkwo KC, et al. Familial adenomatous polyposis syndrome with colorectal cancer in two Nigerians: a report of two cases and review of literature. Pan Afr Med J 2018; 30: 6.
 
[83]  Karstensen JG, Bülow S, Højen H, Jelsig AM, Jespersen N, Andersen KK, Wewer MD, Burisch J, Pommergaard HC. Cancer in Patients With Familial Adenomatous Polyposis: A Nationwide Danish Cohort Study With Matched Controls. Gastroenterology. 2023; 65(3): 573-581.e3.
 
[84]  Long JM, Powers JM, Katona BW. Evaluation of Classic, Attenuated, and Oligopolyposis of the Colon. Gastrointest Endosc Clin N Am. 2022; 32(1): 95-112.
 
Manuscript template